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A Novel 4 bp Deletion Mutation in the FALDH Gene Segregating
in a Turkish Family with Sjo¨gren–Larsson Syndrome
To the Editor:
The Sjo¨gren–Larsson syndrome (SLS; McKusick no. 270200)
is an autosomal-recessively inherited neurocutaneous disorder
characterized by the clinical triad of (congenital) ichthyosis,
spastic diplegia, and mental retardation. Glistening white dots of
the retina are an additional clinical finding that can be found
in a majority of patients (Sjo¨gren and Larsson, 1957; Rizzo,
1993). Biochemically, the syndrome is caused by the deficiency
of microsomal fatty aldehyde dehydrogenase (FALDH). This
enzyme, being a component of the fatty alcohol:NAD1
oxidoreductase (FAO) complex, catalyzes the oxidation of
medium- and long-chain fatty aldehydes to fatty acids (Kelson
et al, 1997).
The FALDH gene has been mapped to chromosome 17p11.2
(Rogers et al, 1995). It spans about 31 kb and consists of 10
exons and 9 introns, resulting in a cDNA that encodes a protein
of 485 amino acids. So far, mutation analysis of the FALDH
gene has almost exclusively been performed in patients from
Swedish and northern European descent. Seven different mutations
have been identified, including two 1 bp deletions, one 2 bp
deletion, two point mutations, an insertion, and a deletion/
insertion (De Laurenzi et al, 1996, 1997; Rizzo et al, 1997;
Sillen et al, 1997; Tsukamoto et al, 1997).
Two patients, a girl (patient 1) aged 7 y and her 6 mo old
brother (patient 2), both presented with congenital ichthyosis.
The girl showed spastic diplegia of the legs and mental
retardation. She had glistening white dots of the retina. The
boy only showed subtle signs of neurologic involvement, and
no retinal abnormalities, which can be explained by his young
age. Their healthy consanguineous parents originate from Turkey.
Two relatives, who are siblings from another consanguineous
couple in this same family, live in Turkey and suffer from
identical clinical symptoms.
The activity of FAO/FALDH was measured in cultured skin
fibroblast homogenates using a medium of the following
composition: 50 mM glycine-NaOH (pH 9.5), 2.5 mM NAD1,
0.5 mg bovine serum albumin per ml, and 12 µM [14C]-
octadecanol. Final protein concentration was 125 µg per ml.
Reactions were allowed to proceed for 40 min at 37°C and
were terminated by adding 2 ml methanol containing 2% (vol/
vol) acetic acid followed by 1 ml chloroform. After vigorous
mixing, phases were separated by low speed centrifugation and
the chloroform phase collected. After evaporation under nitrogen,
the residue was taken up in chloroform/methanol [1/1 (vol/
vol)] and applied to a Siliga Gel 60-plate, using hexane/
diethylether/acetic acid [60/40/1 (vol/vol/vol)] as eluent. Radio-
active octadecanol and octadecanoic acid were quantitated using
an Imaginer and the results obtained were used to calculate the
actual rates.
The genomic DNA from peripheral blood cells was isolated
for genetic analysis using diatoms matrix as described by Boom
et al (1990). A fragment of the FALDH gene including exon 8
and 9 was amplified in a 25 µl polymerase chain reaction
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containing 10 mM Tris-HCl (pH 8.4 at 25°C), 1.0 mM MgCl2,
50 mM KCl, 0.1 mg bovine serum albumin per ml, 0.2 mM
each dNTP, 2.5 U Taq polymerase (Promega, WI) and the
following M13-tagged primers (12.5 pmol each): in8FALDHf-
21M13 59-tgt aaa acg acg gcc agt GGA GTG CAT GTG AGC
TTT CC-39 and in9FALDHrM13rev 59-cag gaa aca gct atg acc
Figure 1. Electropherogram of a control subject, patient 1 (the
identical pattern of patient 2 is not shown). and both parents. The
sequence surrounding the 4 bp deletion (1384–1387delGAAA, indicated
by an arrow) in the FALDH gene is shown.
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ATA TGC ATC TGG CAG CCA TC-39. DNA amplification
was performed in a PTC–100 thermocycler from M.J. Research
(MA), programmed as follows: 120 s at 96°C initial to cycling,
5 cycles of 30 s at 96°C, 30 s at 55°C, and 30 s at 72°C
followed by 25 cycles of 30 s at 96°C and 30 s at 72°C, with
a final extension at 72°C for 10 min. Sequence analysis of the
polymerase chain reaction fragment using BigDye fluorescent
labelled M13 primers was performed on an Applied Biosystems
377 A automated DNA sequencer following the manufacturer’s
protocols (PE Applied Biosystems, Foster City, CA).
The clinical symptoms and the family history of our patients
strongly pointed to the diagnosis of SLS. FALDH activity was
severely deficient in both patients, with a value of 3.3 and
0.0 pmol per min mg protein in patients 1 and 2, respectively
(median FALDH activity in 13 healthy controls: 40.9, range
19.7–54.3 pmol per min mg protein). In both children we
detected a homozygous 4 bp deletion (1384–1387delGAAA) in
exon 9 of the FALDH gene, and heterozygosity was demonstrated
in their parents (Fig 1).
FALDH is a membrane-bound protein with a highly hydro-
phobic amino acid sequence at the carboxy-terminal region,
which is assumed to be necessary for microsomal membrane
anchoring (Masaki et al, 1994; Chang and Yoshida, 1997; Rogers
et al, 1997). The 1384–1387delGAAA mutation leads to
replacement of the carboxy-terminal amino acids [462-
EKLGLLLLTFLGIVAAVLVKAEYY-485] by [462-NSVSCCSLS-
WVL-473], and premature termination of translation at codon
474. The deleted amino acids contain a predicted transmembrane
domain (amino acids 464–480) and membrane retention signal
[481-KAEY-484]. It is likely that the mutation results in a
truncated FALDH that no longer can be anchored to the
microsomal membrane, leading to deficient enzyme activity and
the classical clinical symptoms of SLS.
An alternatively spliced product of the FALDH gene is known,
which contains an additional 125 nucleotides (designated 99)
between exon 9 and exon 10 (Rogers et al, 1997). The mutation
occurs upstream of exon 99, for which reason it will similarly
compromise the translation of both transcripts.
This study contributes to the elucidation of the genetic
backgrounds of SLS, and points to the vital importance of
membrane anchoring for the preservation of FALDH activity.
Promoter/Enhancer Cassettes for Keratinocyte Gene Therapy
To the Editor:
Successful keratinocyte gene therapy requires that transcriptional
units express the therapeutic gene properly in keratinocytes in vivo.
Promoter/enhancer cassettes containing these units should be
examined under in vivo conditions (Cheng et al, 1993). In this
study, we transferred plasmids that were constructed by introducing
various promoter/enhancer cassettes fused with the lacZ (reporter)
gene into keratinocytes by direct injection of naked DNA (Hengge
et al, 1995), and evaluated the cassettes by measuring β-galactosidase
(β-gal) expression.
Plasmid pNASSβ (CLONTECH, Palo Alto, CA) was a pro-
moterless expression vector of the lacZ gene that contained a simian
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virus 40 (SV40) RNA splice site, which is an SV40 polyadenylation
signal. For convenience, we refer to this plasmid as pZ(–). To
synthesize the promoter segments of the mouse 230 kDa bullous
pemphigoid antigen 1 gene, we carried out polymerase chain
reaction (PCR) using a mouse bullous pemphigoid antigen 1 gen-
omic clone as a template (Sawamura et al, 1994). The DNA
segments extending from –1133 to –1, –525 to –1, and 213 to –1
were inserted into pZ(–) to produce p1.1 BPZ, p0.5 BPZ, and
p0.2 BPZ, respectively. We synthesized the promoter segments of
the human K5 and K10 genes by PCR using human genomic
DNA as a template. The K5 and K10 DNA fragments that extended
from –840 to –1 (Ohtuki et al, 1992) and from –1200 to –1 (Rieger
and Franke, 1988), respectively, were inserted into pZ(–) to produce
pK5Z and pK10Z, respectively. All PCR products were sequenced
and no PCR errors were detected from comparisons with the
original sequences. Plasmids pAGS-lacZ and pCMS-lacZ contained
the chicken modified β-actin promoter and 660 bp HincII-HindIII
cytomegalovirus-immediate early (CMV-IE) enhancer/promoter,
respectively (Miyazaki et al, 1989), and these two promoters were
